Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data.

Background: Methods for screening agents earlier in development and strategies for conducting smaller randomized controlled trials (RCTs) are needed.

Methods: We retrospectively applied a tumor growth model to estimate the rates of growth of pancreatic cancer using radiographic tumor measurements or serum CA 19-9 values from 3033 patients with stages III-IV PDAC who were enrolled in 8 clinical trials or were included in 2 large real-world data sets.

Results: g correlated inversely with OS and was consistently lower in the experimental arms than in the control arms of RCTs.

Long-term follow-up experience with adjuvant therapy after irreversible electroporation of locally advanced pancreatic cancer.

Background: Irreversible electroporation (IRE) expands the surgical options for patients with unresectable pancreatic cancer. This study evaluated for differences in survival stratified by type of IRE and receipt of adjuvant chemotherapy.

Methods: Patients with locally advanced pancreatic cancer treated by IRE (2012-2020) were retrospectively included.

Biodiversity effects and rates of spread of nonnative eucalypt woodlands in central California.

Woodlands comprised of planted, nonnative trees are increasing in extent globally, while native woodlands continue to decline due to human activities. The ecological impacts of planted woodlands may include changes to the communities of understory plants and animals found among these nonnative trees relative to native woodlands, as well as invasion of adjacent habitat areas through spread beyond the originally planted areas. Eucalypts (Eucalyptus spp.

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience.

Purpose: We evaluated the efficacy and safety of capecitabine and temozolomide (CAPTEM) in patients with metastatic neuroendocrine tumors (NETs) to the liver. This regimen was based on our studies with carcinoid cell lines that showed synergistic cytotoxicity with sequence-specific dosing of 5-fluorouracil preceding temozolomide (TMZ).

Methods: A retrospective review was conducted of 18 patients with NETs metastatic to the liver who had failed 60 mg/month of Sandostatin LAR™ (100%), chemotherapy (61%), and hepatic chemoembolization (50%).

Treatment of multiple endocrine neoplasia 1/2 tumors: case report and review of the literature.

Background: Neuroendocrine tumors are uncommon tumors that are histopathologically and biologically heterogeneous and include the multiple endocrine neoplasia (MEN) 1 and 2 syndromes. The morbidity of MEN-1 and MEN-2 is often due to the symptomatology of the endocrine hormones produced, and the mortality mainly occurs from hepatic dysfunction incurred by liver metastases. At present, there is essentially no effective cure once the tumor has metastasized to the liver.